The Food and Drug Administration questioned the benefit of using Roche Holding AG’s top-selling cancer drug, Avastin, in breast cancer.

The agency said the magnitude of an improvement seen among women being treated with chemotherapy drugs plus Avastin compared with women being given chemotherapy alone “is not clinically meaningful.” The agency also said there were more serious side effects such as bleeding seen among women being given Avastin. Get the full story »